Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions 
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown 
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power 
Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy 
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates 
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts 
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round 
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China 
Boeing Secures Multi-Billion Dollar Defense Contracts for F-15IA Jets and E-4B Aircraft Support 
BERKELEY, Calif., Feb. 28, 2017 -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced today that Jim Neal, Chief Executive Officer, will present the company’s new strategic initiatives and value drivers at the Cowen and Company 37th Annual Health Care Conference on Tuesday, March 7, 2017 at 11:20 a.m. ET. The conference is being held at the Boston Marriott Copley Place hotel.
A live audio webcast of the presentation can be accessed in the Investors and Media section of XOMA's website at http://investors.xoma.com/events.cfm. An archived version of the webcast will be available via replay for 90 days following the presentation.
About XOMA Corporation
XOMA discovers and develops innovative antibody therapeutics. XOMA has an extensive portfolio of products, programs, and technologies that are the subject of licenses the company has in place with other biotech and pharmaceutical companies. There are more than 20 such programs that are fully funded by partners and could produce milestone payments and royalty payments in the future. XOMA continues to advance Phase 2 development activities for 358, an allosteric monoclonal antibody that reduces insulin receptor activity, as the antibody could have a major impact on the treatment of hyperinsulinism, particularly congenital hyperinsulinism and hypoglycemia after bariatric surgery. For more information, visit www.xoma.com.
CONTACTS: Investor contact: Luke Heagle Pure Communications +1 910-726-1372 [email protected] Media contact: Colin Sanford Pure Communications +1 415-946-1094 [email protected]
